NCCN Guidelines Histiocytic Neoplasms, NCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfNCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfNCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfNCCN clinical practice guidelines in oncology – Histiocytic Neoplasms
https://www.nccn.org/professionals/physician_gls/pdf/histiocytic_neoplasms.pdfHepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma, Transplantation Hematopoietic Growth Factors Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin, Factors Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer, Transplantation Hematopoietic Growth Factors Hepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma Kidney Cancer Lung Cancer Screening Management
https://www.nccn.org/guidelines/permission-to-cite-or-use-nccn-contentHistiocytic Neoplasms Panel, Version: 1.2023 ( Histiocytic Neoplasms ) Date: 2022-12-02 Transparency Panel Disclosures/Attendance Version: 1.2022 ( Histiocytic Neoplasms ) Date: 2021-12-16 Transparency, Panel Disclosures/Attendance Version: 3.2024 ( Uterine Neoplasms ) Date: 2024-06-20, ( Uterine Neoplasms ) Date: 2024-02-29 Transparency Panel Disclosures/Attendance
https://www.nccn.org/guidelines/guidelines-process/transparency-process-and-recommendationsCancers Panel Histiocytic Neoplasms, Myeloproliferative Neoplasms Panel
https://www.nccn.org/guidelines/guidelines-panels-and-disclosure/disclosure-panelsVersion: 3.2024 Histiocytic Neoplasms, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version: 2.2024 Myeloproliferative Neoplasms, Neoplasms Version: 3.2024 Vaginal Cancer
https://www.nccn.org/guidelines/category_1Hepatobiliary Cancers - 1.2023 Hepatocellular Carcinoma - 3.2024 Histiocytic Neoplasms - 2.2024 Hodgkin, Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions - 2.2024 Myeloproliferative Neoplasms - 2.2024, Uterine Neoplasms - 3.2024 Vaginal Cancer - 2.2025 Vulvar Cancer - 4.2024 Waldenström
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-formHepatobiliary Cancers Hepatocellular Carcinoma Histiocytic Neoplasms Hodgkin Lymphoma Kaposi Sarcoma, Mesothelioma: Pleural Multiple Myeloma Myelodysplastic Syndromes Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Myeloproliferative Neoplasms Neuroblastoma, and Thymic Carcinomas Thyroid Carcinoma Uterine Neoplasms Vaginal Cancer Vulvar Cancer, Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms Nasopharyngeal Cancer
https://www.nccn.org/covid-19/resume-screeningVersion 4.2024 Hepatocellular Carcinoma Version 3.2024 Histiocytic Neoplasms Version, Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions Version 2.2024 Myeloproliferative Neoplasms Version 2.2024 Neuroendocrine and Adrenal Tumors, Version 1.2024 Thyroid Carcinoma Version 4.2024 Uterine Neoplasms Version 3.2024
https://www.nccn.org/guidelines/guidelines-with-evidence-blocksRoswell Park Comprehensive Cancer Center Histiocytic Neoplasms, /Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions, Myeloproliferative Neoplasms Thu M. Doan, PharmD, BCOP, of Michigan Rogel Cancer Center Uterine Neoplasms Emily
https://www.nccn.org/compendia-templates/nccn-templates-main/nccn-chemotherapy-order-reviewer-engagementNivolumab for Uterine Neoplasms Submitted by Bristol-Myers Squibb Company on 12/04/2019 Pembrolizumab for Uterine Neoplasms Submitted by Merck & Co., Inc. on 03/19/2020 Pembrolizumab, Pembrolizumab dosing for Uterine Neoplasms Submitted by Merck & Co., Inc. on 04/29/2020 Systemic Therapy Table Headings for Uterine Neoplasms Submitted by GlaxoSmithKline on 05/15/2020, for Uterine Neoplasms Submitted by Merck & Co., Inc. on 06/17/2020 Pembrolizumab
https://www.nccn.org/guidelines/submissions-request-to-the-guidelines-panels/submission-request-historyneoplasms. These clinical resources were also translated into Chinese by leading experts in the region
https://www.nccn.org/docs/default-source/about/annual-report-2023.pdf?sfvrsn=8411082_31